Objective To analyze the clinical value of microRNAs applied in the early diagnosis of pancreatic cancer.Methods The expression of mir-155,mir-196a,mir-181a,mir-181b in three pancreatic cancer cell lines PANC-1,PaCa-2,AsPC-1 pancreatic cancer,normal pancreatic cells and plasmas of 100 patients with pancreatic cancer ,100 normal volunteers were detected by Real-time PCR,and the results were analyzed.The expression of mir-155,mir-196a,mir-181a,mir-181b in 100 pancreatic cancer tissues and 100 normal pancreatic tissues were detected by immunohistochemical,and the results were analyzed. Results Real-timePCR test results showed that compared with normal pancreatic cells,mir-155,mir-196a expression in three pancreatic cancer cells PANC-1,PaCa-2,AsPC-1 were significantly increased(P<0.05).Compared with healthy volunteers,mir-155,mir-196a,mir-181a,mir-181b expression of plasma in pancreatic cancer patients were significantly higher(P<0.05).Immunohistochemistry results showed that mir-155,mir-196a mir-181a and mir-181b expression in pancreatic tissue were significantly higher than that in normal pancreatic tissue (P <0.05 ).Conclusion The expression of mir-155,mir-196a,mir-181a and mir-181b are high in pancreatic cancer tissues and pancreatic cancer cell lines,which are closely related to the development of pancreatic cancer.Those microRNAs are expected to be cancer markers for early diagnosis of,pancreatic cancer,have highly diagnostic value and broad clinical application.

Objective To investigate the relationship factor of livability on Premature Very Low-Birth-Weight-Infant (PVLBWL), for refer to evidences that reduce the mortality and the deformity rate. Methods The group 116 PVLBWL cases, being in our hospital hear five years, divide into three team according to the weight, and analyze the review clinical data of the cases (from 1993.1 to 1998.1). Results There are 86 cases that had cured and left hospital in the group. The cure rate is 74.1%(86/116). It is rise along with the weight increase (P

Objective To study the effects of Forkhead box protein M1 (FoxM1) down regulation by small interfering RNA(siRNA) on chemosensitivity and mechanism of human pancreatic cancer cell and its mechanism.Methods Three FoxM1 siRNAs were designed and constructed.All cancer cells were divided into different groups,after transfected with FoxM1 siRNA for different time,the cultured cells were harvested to carry on the next tests.Expression of FoxM1 were determined by red-time PCR and Western blot,and prolifearion and chemosensitivity were evaluated by MTT assay,and the phosphorylation of Akt protein was examined by Western blot.Results FoxM1 siRNA could down-regulate the FoxM1 expression in a dose-and time-dependent manner.The MTF results showed that the inhibit rates was 17.78％,17.56％,35.39％,52.81％,70.98％ indifferentgroups [Con-A + Gemcitabine,Con-B + Gemcitabine,siRNA (3.125nM) + Gemcitabine,siRNA (6.25nM) + Gemcitabine and siRNA(12.5nM) + Gemcitabine,respectively.The phosphorylation of Akt protein was inhibited in a dose-dependent manner.Conclusions FoxM1 siRNA could sensitize human pancreaticr cancer cells chemotherapy sensitivity,it is the one of the important mechanisms through down-regulate Akt phosphorylated levels,but the molecular mechanism need to be explored further.

Objective To study a new operative method for treatment of hepatic venous occlasion without (associated) pathologic change of inferior vena cava or long-segment stricture. Methods A total of 44 cases of Budd-chiari syndrome with hepatic venous occlusion without pathologic change or long-segment stricture of (inferior) vena cava underwent combined mesocaval C-shunt, ligation of splenic artery, and esophagogastric (devascularization).Results Pre-shunt portal venous pressure was 36cmH2O(31~45 cmH2O, 1cmH2O=0.0098kPa) and post-shunt pressure fell to 26 cmH2O(21~33 cmH2O),the mean reduction was 10 cmH2O. One patient died of liver failure. A slight degree of hepatic encephalopathy occurred in 2patients who recovered after conservative treatment.Chylorrhea occurred in 4 patients, and it spontaneously disappeared 7d to 3.5months after operation. 39 patients(88.6% follow up) were followed up for 6months to 7years , and there was no case of recurrent bleeding nor hepatic encephalopathy. Ascites disappeared in 31cases,and was markedly reduced in 7 cases .The prosthetic grafts were patent as shown by color Doppler ultra sound in all followed-up patients.Conclusions This operation is simple and effective for B-CS with hepatic venous (occlusion) but not associated with inferior vena caval pathologic change or long-segment stricture.

Objective To establish a liquichip method for detecting 6 sub-genotypes of hepatitis C virus(HCV),including 1a, 1b,2a,3a,3b and 6a.Methods The coupling method of PCR amplification and nucleic acid probe was established.The PCR product and the microspheres mixture of the coupled nucleic acid probe were hybridized for establishing the liquichip detection method.The sensitivity and specificity of the established liquichip detection method were evaluated.Nucleic acid in 93 serum samples was detec-ted by this method..Results The established HCV nuclei acid liquichip genotype detection method had the higher specificity and sensitivity,which could detect and classfy 6 HCV sub-genotypes.The sensitivity for HCV 1a,3a and 6a sub-genotypes was 1× 105 copies/PCR;the sensitivity for HCV 1b,2a and 3b sub-genotypes was 1×104 copies/PCR.The detection results in 93 serum samples showed that the this genotyping method had the characteristics of high throughput,rapidness,sentsitivity and specificity. Conclusion This method can be used for the simultaneous and quick detection of 6 HCV sub-genotypes and provides a new meth-od for the genotyping detection of HCV.

Objective To investigate the effect of interventional therapy for Budd Chiari Syndrome(BCS). Methods 355 patients with BCS were examined with phlebography of inferior vena cava(PIVC) and percutaneous transhepatic hepatovenography(PTHV).The interventional procedures were based on the pathological changes of inferior vena cava(IVC) and main hepatic veins(MHVs).The procedures included PTA and/or stent placement of IVC,percutaneous transhepatic recanalization and dilation (PTHRD)of MHVs ,and percutaneous transjugular or transinferior vena cava recanalization and dilation with stent placement of MHVs(PTJRD and PTIRD ), percutaneous transhepatic recanalization or transinferior vena cava recanalization and dilation with stent placement of associated hepatic veins(AHVs). Results The success rate and recurrence rate were 96.0%(240/250) and 10.0 %(24/240), respectively, in PTA; the success rate was 91.4%(32/35 ) in PTHRD of MHVs; 90.0%(18/20 ) in PTJRD and PTIRD of MHVs , 100.0%(10/10) in PTJRD and PTIRD of AHVs; 90.0 %( 9/10 ) in PTA and stent placement plus PTHRD of AHVs. Severe complications occurred in 10 cases (2.8%). Conclusions Interventional therapy is simple, safe and effective for patients with some types of Budd Chiari Syndrome.

Health service is an important part of the integrated development of the Yangtze River Delta. Taking the cooperation practice between Shanghai Tenth People′s Hospital and Suzhou Yinshanhu Hospital as an example, this article introduced the multi-agent cooperation mode of the loose medical alliance including the government, urban hospitals and cross provincial grassroots medical institutions. Among them, the local government provided policy, fund guarantee and guidance, the urban hospital exported management ideas, medicine talents and technologies, and the primary hospital conducted dual training by inviting in and going out to achieve double growth. Through the high gap cooperation between tertiary hospital and primary hospital, Yinshanhu hospital had been comprehensively developed. The loose medical alliance with multi subject coordination and cross region could give full play to the advantages of the loose healthcare alliance mode, achieve multi-win, and have reference significance for promoting the regional integration of medical and health services in the Yangtze River Delta.

Objective:To investigate the regulation of Parkin-dependent mitophagy mediated by calcyclin-binding protein and Siah-1 interacting protein (CacyBP/SIP) on apoptosis and cycle of dopaminergic (DA) neurons.Methods:SH-SY5Y cells were divided into model group, control group and CacyBP/SIP group; cells in the model group were treated with 1-methyl-4-phenylpyridine (MPP +, 0.5 mmol/L) for 24 h, and cells in the control group and CacyBP/SIP group were transfected with empty lentivirus or CacyBP/SIP-sgRNA lentivirus on the basis of MMP +(0.5 mmol/L) treatment for 24 h, respectively. Western blotting was used to detect the protein expression levels of CacyBP/SIP, microtubule-associated protein l light chain 3 (LC3), lysosome-associated membrane protein 2 (LAMP2), phosphatase and tensin homolog ten induced kinase 1 (Pink1), Parkin, P53, Bcl-2, and Bax; flow cytometry was used to detect the cell apoptosis and cycle; immunofluorescent single staining was used to detect the expressions of LC3 and LAMP2; immunofluorescent double staining was used to detect the coexpressions of CacyBP/SIP and Parkin. Results:As compared with the model group and control group, the CacyBP/SIP group had significant reduction in protein expressions of CacyBP/SIP, LAMP2, Pink1, and Parkin, LC3-II/I ratio, immunofluorescent staining intensities of LC3-II and LAMP2, and Bcl-2 protein expressions ( P<0.05). As compared with the model group and control group, the CacyBP/SIP group had significantly increased Bax protein expression, significantly decreased Bcl-2/Bax ratio, significantly increased apoptosis rate, significantly increased P53 protein expression, significantly increased proportion of cells at G1 phase, and significantly decreased immunofluorescent intensity of CacyBP/SIP and Parkin co-expressions ( P<0.05). Conclusion:After knocking out CacyBP/SIP gene, the decrease of Parkin protein leads to cell cycle being arrested at G1 stage, and mediates the decrease of Parkin-dependent mitochondrial autophagy, thereby leading to increased cell apoptosis.

Humans ; COVID-19 ; SARS-CoV-2